Literature DB >> 18483099

Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.

Walter Jentzen1, Lutz Freudenberg, Ernst G Eising, Wilfried Sonnenschein, Jochen Knust, Andreas Bockisch.   

Abstract

UNLABELLED: Iodine kinetics and lesion dose per administered 131I activity (LDpA) of differentiated thyroid cancer metastases were determined using 124I PET. These data were analyzed to derive an optimized dosimetry protocol.
METHODS: We evaluated the time-activity-concentration curves of 37 lesions in 17 patients who had undergone thyroidectomies. LDpA determination involved 124I PET images acquired at 4, 24, 48, 72, and 96 h after intake of a capsule containing 20-40 MBq of 124I. A combination of a linear and a monoexponential or a monoexponential function only parameterized the time-activity-concentration curves. The LDpAs, calculated using data from all 5 PET time points, served as reference. The lesions were classified into 3 groups, according to potential for cure with 131I therapy: low (< or =5 Gy GBq(-1); n = 14), medium (between 5 and 10 Gy GBq(-1); n = 9), or high LDpAs (>10 Gy GBq(-1); n = 14). Using the reference approach, the differences in the empiric kinetic parameters within the LDpA groups were evaluated. The reference LDpAs were compared with those derived from only 2, 3, or 4 PET data points and from 1 adapted 2-point approach. Lin's concordance correlation coefficient (rho c) and the mean absolute percentage deviation in LDpAs were used to assess agreement between simplified and reference approaches.
RESULTS: The effective 124I half-life, linear activity-concentration rate (alpha), and 24-h activity concentration (CpA) (the latter 2 per administered 124I activity) differed significantly among the LDpA groups (P < 0.05). LDpAs correlated with 24-h CpAs (r = 0.94, P < 0.001). Using the 4-, 24-, and 96-h measurements, a rho c value of greater than or equal to 0.90 was found, and the mean absolute percentage deviation was less than or equal to 16%. Similar statistical values were obtained for the adapted approach, which was based on 24- and 96-h PET data points only.
CONCLUSION: Lesion classification into LDpA groups was feasible using a single PET scan at approximately 24 h. Because of the highly variable kinetics, 1 additional measurement at approximately 96 h was needed to obtain a sufficiently reliable LDpA estimate. The adapted 24-96-h approach appears to be the optimal 124I protocol and is a reliable simplification of the 5-point protocol.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483099     DOI: 10.2967/jnumed.107.047159

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  31 in total

Review 1.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 2.  Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.

Authors:  Massimo Salvatori; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04       Impact factor: 9.236

3.  Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT.

Authors:  Youngho Seo; Yoonsuk Huh; Shih-Ying Huang; J Miguel Hernandez-Pampaloni; Randall A Hawkins; W Clay Gustafson; Kieuhoa T Vo; Katherine K Matthay
Journal:  Med Phys       Date:  2019-03-12       Impact factor: 4.071

4.  Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck.

Authors:  James Nagarajah; Walter Jentzen; Verena Hartung; Sandra Rosenbaum-Krumme; Christian Mikat; Till Alexander Heusner; Gerald Antoch; Andreas Bockisch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-08       Impact factor: 9.236

5.  Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer.

Authors:  Laurent Dercle; Désirée Deandreis; Marie Terroir; Sophie Leboulleux; Jean Lumbroso; Martin Schlumberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06       Impact factor: 9.236

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.

Authors:  Joseph J Grudzinski; Ronald R Burnette; Jamey P Weichert; Robert Jeraj
Journal:  Cancer Biother Radiopharm       Date:  2010-08       Impact factor: 3.099

8.  Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?

Authors:  I Binse; T D Poeppel; M Ruhlmann; B Gomez; L Umutlu; A Bockisch; S J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-19       Impact factor: 9.236

9.  Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.

Authors:  R F Hobbs; W Jentzen; A Bockisch; G Sgouros
Journal:  Q J Nucl Med Mol Imaging       Date:  2013-03       Impact factor: 2.346

10.  ¹²⁴I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy ¹³¹I SPECT/CT.

Authors:  Cecile de Pont; Servais Halders; Jan Bucerius; Felix Mottaghy; Boudewijn Brans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.